Understanding Triple-Negative Breast Cancer (TNBC) and Treatment Resistance
In this session, Dr. Meenakshi Anurag will discuss her research on triple-negative breast cancer (TNBC), focusing on the molecular mechanisms behind chemotherapy resistance. Through proteogenomic analysis, her lab has identified key biomarkers, such as LIG1 and POLD1, linked to treatment outcomes in TNBC. Join us to explore how these insights aim to enhance personalized treatment strategies for patients facing this challenging cancer subtype.
Speaker
-
Meenakshi Anurag, Ph.D.Assistant Professor, Department of Medicine, Baylor College of MedicineDr. Meenakshi Anurag’s research focuses on improving cancer diagnosis, treatment, and survival through precision data science. With over seven years of bioinformatics experience, she investigates the molecular diversity of cancers, including rare types like male breast cancer, using multi-omics and big data analysis.
Her work has revealed DNA damage repair defects as drivers of endocrine treatment resistance in breast cancer. She is also exploring immune tolerance factors in therapy-resistant, estrogen receptor-positive cancers, integrating genomic and clinical data to uncover new therapeutic strategies.
